The Medical University of South Carolina   Medical Center  ·  College of Medicine ·  Directory   
Department of Pathology Banner MUSC Logo


Our Mission

To serve patients, health care providers, research scientists, scholars, and society by providing excellence and innovation in diagnostic services and educational resources in a respectful, professional and culturally diverse atmosphere.

Our Vision

To become a preeminent leader in academic anatomic and clinical pathology while translating basic science discovery to improved clinical care.



Hiu Wing Cheung, Ph.D.

Hiu Wing Cheung, Ph.D.

Assistant Professor
Department of Pathology & Laboratory Medicine
Office: Bioengineering Building Room BE413
Phone: (843) 876-2231
Fax: (843) 792-0368

EDUCATION:

B.Sc. (Biochemistry), 1999, The University of Hong Kong
M.Phil., 2002, The University of Hong Kong
Ph.D., 2006, The University of Hong Kong

RESEARCH INTERESTS:

Targeted therapies that exploit oncogene addiction have shown clinical benefit in specific cancer types. Recent advances in genomic tools enable researchers to deploy comprehensive approaches to identify all forms of genetic alterations present in cancers. However, the number and complexity of data that emerge from these efforts complicate endeavors to identify biologically relevant alterations critical for cancer development and maintenance. A powerful complementary approach is to characterize the functional basis of cancers, by performing systematic gain-of-function and loss-of-function genetic screens to identify genes involved in malignant transformation of cancer cells.

My laboratory focuses on developing and applying genome-scale tools to characterize cancer genomes and to systematically study the molecular mechanisms underlying cancer development and vulnerabilities. For instances, a highly parallel, pooled RNA interference screening method was developed to identify genetic vulnerabilities across hundreds of cancer cell lines. Through a systematic analysis, we have identified several novel oncogenes, such as CRKL as a novel target of amplification in non-small cell lung cancer, and ID4 and PAX8 as lineage-specific survival factors in ovarian cancers. We are currently performing detailed characterization of the oncogenic signaling mechanisms. Overall, the integration of functional genomics approach with the ongoing genome characterization efforts will illustrate an efficient path to identify new cancer vulnerabilities, with the overarching goal to bring the promise of genomic revolution to impact cancer medicine.

FUNDING:

Start-up fund, Department of Pathology and Laboratory Medicine, Medical University of South Carolina.
2012 V Scholar Grant, The V Foundation for Cancer Research.
2013 American Cancer Society Institutional Research Grant #IRG-97-219-14, American Cancer Society.
2013 Pilot Study Award, The Marsha Rivkin Center for Ovarian Cancer Research.
2014-2017 Liz Tiberis Early Career Award, Ovarian Cancer Research Fund.

SELECTED PUBLICATIONS:

  1. Cheung HW, Ling MT, Tsao SW, Wong YC and Wang X (2004). Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 25(6):881-7.
  2. Cheung HW, Ching YP, Nicholls JM, Ling MT, Wong YC, Hui N, Cheung AL, Tsao SW, Wang Q, Jin DY and Wang X (2005). Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. Molecular Carcinogenesis 43(4):237-45.
  3. Cheung HW, Jin DY, Ling MT, Wong YC, Wang Q, Tsao SW and Wang X (2005). MAD2 expression induces chemosensitization to a DNA damaging agent, cisplatin, in nasopharyngeal carcinoma cells. Cancer Research 65(4):1450-8.
  4. Cheung HW, Chun AC, Wang Q, Deng W, Hu L, Guan XY, Nicholls JM, Ling MT, Wong YC, Tsao SW, Jin DY and Wang X (2006). Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA damaging agents. Cancer Research 66(8):4357-67.
  5. Wang X, Cheung HW and Wong YC (2008). Mitotic checkpoint defects in human cancers and their implications to chemotherapy. Front Bioscience 13:2103-14. Review.
  6. *Luo B, *Cheung HW, *Subramanian A, Sharifnia T, Okamoto M, Yang X, Hinkle G, Boehm JS, Beroukhim R, Weir BA, Mermel C, Barbie DA, Awad T, Zhou X, Nguyen T, Piqani B, Li C, Golub TR, Meyerson M, †Hacohen N, †Hahn WC, †Lander ES, †Sabatini DM and †Root DE (2008). Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 105(51):20380-5. *These authors contributed equally to the work. †These senior authors contributed equally to the work.
  7. *Cheung HW, *Cowley GS, *Weir BA, *Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, Jiang G, Hsiao J, Mermel CH, Getz G, Barretina J, Gopal S, Tamayo P, Gould J, Tsherniak A, Stransky N, Luo B, Ren Y, Drapkin R, Bhatia SN, Mesirov JP, Golub TR, Garraway LA, Meyerson M, †Lander ES, †Root DE, †Hahn WC (2011). Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci USA 108(30):12372-7. *These authors contributed equally to the work. †These senior authors contributed equally to the work.
  8. Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, Butaney M, Sequist LV, Luo B, Engelman JA, Root DE, Meyerson M, Golub TR, Jänne PA and Hahn WC (2011). Amplification of CRKL induces transformation and EGFR inhibitor resistance in human non-small cell lung cancers. Cancer Discovery 1(7):608-625.
  9. *Ren Y, *Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, Hirsch MS, Mesirov JP, Drapkin R, Root DE, Lo J, Fogal V, Ruoslahti E, †Hahn WC and †Bhatia SN (2012). Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer target ID4. Science Translational Medicine 4(147):147ra112. *These authors contributed equally to the work. †These senior authors contributed equally to the work.
  10. *Dunn GP, *Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch M, Vazquez F, Root DE, Beroukhim R, Drapkin R, Hahn WC (2014). In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci USA 111(3):1102-7.*These authors contributed equally to the work.


Pathology Divisions
Anatomic Pathology
Laboratory Medicine
Research

Department of Pathology and Laboratory Medicine Chairman Dr. Steven L. Carroll
Message from the Chairman


News


Upcoming Events


Copyright 2011 MUSC Department of Pathology and Laboratory Medicine